Oncocyte to Begin Trading on the Nasdaq Stock Market on

to Begin Trading on the Nasdaq Stock Market on March 8, 2021

Calif., Feb. 23, 2021 - Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to

provide actionable answers at critical decision points across the cancer care continuum, has been approved for listing on the

Nasdaq Global Market. The Company's shares will continue to trade under its current symbol, "OCX," with trading

on Nasdaq expected to commence at the open of market on Monday, March 8, 2021. Oncocyte's shares will continue to trade

on the NYSE American Exchange until the close of trading on Friday, March 5, 2021.

on the Nasdaq, a market known as the home of innovative and growing global companies, is an important milestone for our company,"

said Ron Andrews, Chief Executive Officer of Oncocyte. "As we continue our growth, we believe there are many potential benefits

of listing on this well-respected global market, including increased visibility, better market liquidity, exposure to more institutional

investors, and ultimately improved shareholder value. Also, the prospect of being included in one or more Nasdaq healthcare indexes

is another significant potential advantage of listing."

Oncocyte Corporation

is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer

care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve

outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present

multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx ,

a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts

benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO , a gene expression test that assesses the tumor

microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical

trials. To complement DetermaIO, the Company anticipates launching DetermaTx , a test to assess mutational status of a tumor

to help identify the appropriate targeted therapy, in the second half of 2021. The Company also plans to continue with the development

of DetermaMx as it seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide

pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug

development process.

DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation.

Forward Looking Statements

cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including,

but not limited to statements that contain words such as "will," "believes," "plans," "anticipates,"

"expects," "estimates," "may," and similar expressions) are forward-looking statements. These

statements include those pertaining to the potential benefits of listing on the Nasdaq Global Market, unexpected delays, unexpected

expenditures, indemnities or other liabilities, or other unanticipated difficulties resulting from technology transfers, commercial

plans, invalidation, termination or reduction of any licensed intellectual property rights, or infringement of third party intellectual

property rights, acquisitions, implementation and results of research, development, clinical trials and studies, commercialization

plans, future financial and/or operating results, and future opportunities for Oncocyte or any distributor, along with other statements

about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve

risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor's financial

and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products,

uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic

system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor's

supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions,

and the need to obtain third party reimbursement for patients' use of any diagnostic tests we commercialize in applicable

jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory

or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources

to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results

may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should

be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk

Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission filings, which are

available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak

only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that

occur or circumstances that exist after the date on which they were made, except as required by law.